Agmatine: clinical applications after 100 years in translation
详细信息 查看全文
- 作者：John E. Piletz ; Feyza Aricioglu ; Juei-Tang Cheng ; Carolyn A. Fairbanks ; Varda H. Gilad ; Britta Haenisch ; Angelos Halaris ; Samin Hong ; Jong Eun Lee ; Jin Li ; Ping Liu ; Gerhard J. Molderings ; Ana L¨²cia S. Rodrigues ; Joseph Satriano ; Gong Je Seong ; George Wilcox ; Ning Wu ; Gad M. Gilad
- 刊名：Drug Discovery Today
- 出版年：2013
- 出版时间：September, 2013
- 年：2013
- 卷：18
- 期：17-18
- 页码：880-893
- 全文大小：674 K
文摘
Agmatine (decarboxylated arginine) has been known as a natural product for over 100 years, but its biosynthesis in humans was left unexplored owing to long-standing controversy. Only recently has the demonstration of agmatine biosynthesis in mammals revived research, indicating its exceptional modulatory action at multiple molecular targets, including neurotransmitter systems, nitric oxide (NO) synthesis and polyamine metabolism, thus providing bases for broad therapeutic applications. This timely review, a concerted effort by 16 independent research groups, draws attention to the substantial preclinical and initial clinical evidence, and highlights challenges and opportunities, for the use of agmatine in treating a spectrum of complex diseases with unmet therapeutic needs, including diabetes mellitus, neurotrauma and neurodegenerative diseases, opioid addiction, mood disorders, cognitive disorders and cancer.